
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics is expected to have enough financial resources to support operations until at least the second quarter of 2027, with the potential launch of their drug nomlabofusp in mid-2027 being a key driver of future stock growth. However, the company may need additional funding sources in order to fully support the drug launch and maximize its potential. The upcoming regulatory updates for nomlabofusp are also seen as a major driver for the company's stock in the near future.
Bears say
Larimar Therapeutics is at a high risk for failure with its single product development focus and potential delays or termination of development campaigns without adequate financing. Additionally, regulatory requirements and the need for additional studies could limit the company's ability to gain market traction and generate revenue. Investors should approach this stock with caution and thoroughly evaluate the company's financial stability and ability to bring its product to market before making any investment decisions.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares